The DOI matches its Crossref record; 298 of the 298 references it cites were found in a registry or an index.
TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants – past, present and future
Open accessAbstract
Tumor Necrosis Factor (TNF), initially known for its tumor cytotoxicity, is a potent mediator of inflammation, as well as many normal physiological functions in homeostasis and health, and anti-microbial immunity. It also appears to have a central role in neurobiology, although this area of TNF biology is only recently emerging. Here, we review the basic biology of TNF and its normal effector functions, and discuss the advantages and disadvantages of therapeutic neutralization of TNF - now a commonplace practice in the treatment of a wide range of human inflammatory diseases. With over ten years of experience, and an emerging range of anti-TNF biologics now available, we also review their modes of action, which appear to be far more complex than had originally been anticipated. Finally, we highlight the current challenges for therapeutic intervention of TNF: (i) to discover and produce orally delivered small molecule TNF-inhibitors, (ii) to specifically target selected TNF producing cells or individual (diseased) tissue targets, and (iii) to pre-identify anti-TNF treatment responders. Although the future looks bright, the therapeutic modulation of TNF now moves into the era of personalized medicine with society's challenging expectations of durable treatment success and of achieving long-term disease remission.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bioavailability of curcumin: Problems and promises
Anand, P., Kunnumakkara, A. B., Newman, R. A., & Aggarwal, B. B. (2007) · Molecular Pharmaceutics · doi:10.1021/mp700113r · Cited by 5,543 · cited 1×
“However, it is pharmacologically well characterized and considered safe even at high concentrations [186,187].”
BackgroundAn endotoxin-induced serum factor that causes necrosis of tumors
Carswell, E. A., Old, L. J., Kassel, R. L., Green, S., Fiore, N., & Williamson, B. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.9.3666 · Cited by 4,532
A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD
Enari, M., Sakahira, H., Yokoyama, H., Okawa, K., Iwamatsu, A., & Nagata, S. (1998) · Nature · doi:10.1038/34112 · Cited by 3,189
A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells
Black, R. A., Rauch, C. T., Kozlosky, C. J., Peschon, J. J., Slack, J. L., Wolfson, M. F., Castner, B. J., Stocking, K. L., Reddy, P., Srinivasan, S., et al. (1997) · Nature · doi:10.1038/385729a0 · Cited by 3,149
Muzio, M., Chinnaiyan, A. M., Kischkel, F. C., O'Rourke, K., Shevchenko, A., Ni, J., Scaffidi, C., Bretz, J. D., Zhang, M., Gentz, R., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81266-0 · Cited by 3,046
Wang, C.-Y., Mayo, M. W., Korneluk, R. G., Goeddel, D. V., & Baldwin, A. S. (1998) · Science · doi:10.1126/science.281.5383.1680 · Cited by 2,711
Beutler, B., Milsark, I. W., & Cerami, A. C. (1985) · Science · doi:10.1126/science.3895437 · Cited by 2,352
Boldin, M. P., Goncharov, T. M., Goltseve, Y. V., & Wallach, D. (1996) · Cell · doi:10.1016/s0092-8674(00)81265-9 · Cited by 2,292
Wilson, A. G., Symons, J. A., McDowell, T. L., McDevitt, H. O., & Duff, G. W. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.7.3195 · Cited by 2,218
Weinblatt, M. E., Kremer, J. M., Bankhurst, A. D., Bulpitt, K. J., Fleischmann, R. M., Fox, R. I., Jackson, C. G., Lange, M., & Burge, D. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901283400401 · Cited by 2,085
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
Baert, F., Noman, M., Vermeire, S., Van Assche, G., D' Haens, G., Carbonez, A., & Rutgeerts, P. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020888 · Cited by 2,015
The TNF receptor 1-associated protein TRADD signals cell death and NF-κB activation
Hsu, H., Xiong, J., & Goeddel, D. V. (1995) · Cell · doi:10.1016/0092-8674(95)90070-5 · Cited by 2,012
Campo, E., Swerdlow, S. H., Harris, N. L., Pileri, S., Stein, H., & Jaffe, E. S. (2011) · Blood · doi:10.1182/blood-2011-01-293050 · Cited by 2,008
Hsu, H., Shu, H.-B., Pan, M.-G., & Goeddel, D. V. (1996) · Cell · doi:10.1016/s0092-8674(00)80984-8 · Cited by 1,998
Weinblatt, M. E., Keystone, E. C., Furst, D. E., Moreland, L. W., Weisman, M. H., Birbara, C. A., Teoh, L. A., Fischkoff, S. A., & Chartash, E. K. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10697 · Cited by 1,757
Klareskog, L., van der Heijde, D., de Jager, J. P., Gough, A., Kalden, J., Malaise, M., Mola, E. M., Pavelka, K., Sany, J., Settas, L., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15640-7 · Cited by 1,751
Elliott, M. J., Maini, R. N., Feldmann, M., Kalden, J. R., Antoni, C., Smolen, J. S., Leeb, B., Breedveld, F. C., Macfarlane, J. D., Bijl, J. A., et al. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90628-9 · Cited by 1,682
Chung, E. S., Packer, M., Lo, K. H., Fasanmade, A. A., & Willerson, J. T. (2003) · Circulation · doi:10.1161/01.cir.0000077913.60364.d2 · Cited by 1,644
Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1.
Dinarello, C. A., Cannon, J. G., Wolff, S. M., Bernheim, H. A., Beutler, B., Cerami, A., Figari, I. S., Palladino, M. A., & O'Connor, J. V. (1986) · The Journal of experimental medicine · doi:10.1084/jem.163.6.1433 · Cited by 1,472
Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice
Kaplan, D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., & Schreiber, R. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7556 · Cited by 1,465 · cited 1×
“, personal communication) and although differences in spontaneous tumor development are not always evident until moved onto a tumor suppressor gene deficient background [253], even p53- and”
BackgroundTranscription Factor ATF2 Regulation by the JNK Signal Transduction Pathway
Gupta, S., Campbell, D., Dérijard, B., & Davis, R. J. (1995) · Science · doi:10.1126/science.7824938 · Cited by 1,438
McDermott, M. F., Aksentijevich, I., Galon, J., McDermott, E. M., Ogunkolade, B. W., Centola, M., Mansfield, E., Gadina, M., Karenko, L., Pettersson, T., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80721-7 · Cited by 1,408
Self-citationActivation of Transcription Factor NF-κB Is Suppressed by Curcumin (Diferuloylmethane)
Singh, S., & Aggarwal, B. B. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.42.24995 · Cited by 1,386
Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α
Moss, M. L., Jin, S.-L. C., Milla, M. E., Burkhart, W., Carter, H. L., Chen, W.-J., Clay, W. C., Didsbury, J. R., Hassler, D., Hoffman, C. R., et al. (1997) · Nature · doi:10.1038/385733a0 · Cited by 1,378
Grell, M., Douni, E., Wajant, H., Löhden, M., Clauss, M., Maxeiner, B., Georgopoulos, S., Lesslauer, W., Kollias, G., Pfizenmaier, K., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90192-2 · Cited by 1,325
Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors
Thome, M., Schneider, P., Hofmann, K., Fickenscher, H., Meinl, E., Neipel, F., Mattmann, C., Burns, K., Bodmer, J.-L., Schröter, M., et al. (1997) · Nature · doi:10.1038/386517a0 · Cited by 1,315
Waage, A., Brandtzaeg, P., Halstensen, A., Kierulf, P., & Espevik, T. (1989) · The Journal of experimental medicine · doi:10.1084/jem.169.1.333 · Cited by 1,173
Certolizumab Pegol for the Treatment of Crohn's Disease
Sandborn, W. J., Feagan, B. G., Stoinov, S., Honiball, P. J., Rutgeerts, P., Mason, D., Bloomfield, R., & Schreiber, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067594 · Cited by 1,143
Aggarwal, B. B., & Sung, B. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.11.002 · Cited by 1,140 · cited 1×
“Curcumin is a naturally produced compound that inhibits TNF and other pro-inflammatory cytokines including TNF, IL-1b and IL-6; it is a broad-acting anti-TNF and anti-inflammatory nutraceutical, generally consumed orally via natural food spices and/or via medicinal preparations (for reviews see [184,185]).”
BackgroundRutgeerts, P., D'Haens, G., Targan, S., Vasiliauskas, E., Hanauer, S. B., Present, D. H., Mayer, L., Van Hogezand, R. A., Braakman, T., DeWoody, K. L., et al. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70332-x · Cited by 1,080
Rothe, M., Wong, S. C., Henzel, W. J., & Goeddel, D. V. (1994) · Cell · doi:10.1016/0092-8674(94)90532-0 · Cited by 1,054
TRAF2-Mediated Activation of NF-κB by TNF Receptor 2 and CD40
Rothe, M., Sarma, V., Dixit, V. M., & Goeddel, D. V. (1995) · Science · doi:10.1126/science.7544915 · Cited by 1,051
Schütze, S., Potthoff, K., Machleidt, T., Berkovic, D., Wiegmann, K., & Krönke, M. (1992) · Cell · doi:10.1016/0092-8674(92)90553-o · Cited by 1,046
Maintenance Therapy with Certolizumab Pegol for Crohn's Disease
Schreiber, S., Khaliq-Kareemi, M., Lawrance, I. C., Thomsen, O. Ø., Hanauer, S. B., McColm, J., Bloomfield, R., & Sandborn, W. J. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062897 · Cited by 1,043
Involvement of linear polyubiquitylation of NEMO in NF-κB activation
Tokunaga, F., Sakata, S.-I., Saeki, Y., Satomi, Y., Kirisako, T., Kamei, K., Nakagawa, T., Kato, M., Murata, S., Yamaoka, S., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1821 · Cited by 942
Linear ubiquitination prevents inflammation and regulates immune signalling
Gerlach, B., Cordier, S. M., Schmukle, A. C., Emmerich, C. H., Rieser, E., Haas, T. L., Webb, A. I., Rickard, J. A., Anderton, H., Wong, W. W.-L., et al. (2011) · Nature · doi:10.1038/nature09816 · Cited by 940
Martinon, F., & Tschopp, J. (2004) · Cell · doi:10.1016/j.cell.2004.05.004 · Cited by 938
Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial
Sandborn, W. J., Hanauer, S. B., Katz, S., Safdi, M., Wolf, D. G., Baerg, R. D., Tremaine, W. J., Johnson, T., Diehl, N. N., & Zinsmeister, A. R. (2001) · Gastroenterology · doi:10.1053/gast.2001.28674 · Cited by 910
Characterization of receptors for human tumour necrosis factor and their regulation by γ-interferon
Aggarwal, B. B., Eessalu, T. E., & Hass, P. E. (1985) · Nature · doi:10.1038/318665a0 · Cited by 884
Bulua, A. C., Simon, A., Maddipati, R., Pelletier, M., Park, H., Kim, K.-Y., Sack, M. N., Kastner, D. L., & Siegel, R. M. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20102049 · Cited by 860 · cited 1×
“However, abnormal ER retention [131], mitochrondrial reactive oxygen species [132], ER stress, and the stress response to ‘‘unfolded’’ or aggregated proteins also contribute to TRAPS pathogenesis [133]; for review see [134].”
BackgroundA Domain in TNF Receptors That Mediates Ligand-Independent Receptor Assembly and Signaling
Chan, F. K.-M., Chun, H. J., Zheng, L., Siegel, R. M., Bui, K. L., & Lenardo, M. J. (2000) · Science · doi:10.1126/science.288.5475.2351 · Cited by 856
McCoy, M. K., & Tansey, M. G. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-45 · Cited by 847
Adverse effects of biologics: a network meta-analysis and Cochrane overview
Singh, J. A., Wells, G. A., Christensen, R., Tanjong Ghogomu, E., Maxwell, L. J., MacDonald, J. K., Filippini, G., Skoetz, N., Francis, D. K., Lopes, L. C., et al. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008794.pub2 · Cited by 823
McInnes, I. B., Kavanaugh, A., Gottlieb, A. B., Puig, L., Rahman, P., Ritchlin, C., Brodmerkel, C., Li, S., Wang, Y., Mendelsohn, A. M., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60594-2 · Cited by 807
The two different receptors for tumor necrosis factor mediate distinct cellular responses.
Tartaglia, L. A., Weber, R. F., Figari, I. S., Reynolds, C., Palladino, M. A., & Goeddel, D. V. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.20.9292 · Cited by 807
Zhou, D., Huang, C., Lin, Z., Zhan, S., Kong, L., Fang, C., & Li, J. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2013.11.004 · Cited by 778 · cited 1×
“vely activated and largely tolerogenic M2 cell-subtype [143,144].”
BackgroundHaas, T. L., Emmerich, C. H., Gerlach, B., Schmukle, A. C., Cordier, S. M., Rieser, E., Feltham, R., Vince, J., Warnken, U., Wenger, T., et al. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.10.013 · Cited by 775
Reactive oxygen species in cardiovascular disease
Sugamura, K., & Keaney (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.05.004 · Cited by 769
Philip, R., & Epstein, L. B. (1986) · Nature · doi:10.1038/323086a0 · Cited by 767
SHARPIN forms a linear ubiquitin ligase complex regulating NF-κB activity and apoptosis
Ikeda, F., Deribe, Y. L., Skånland, S. S., Stieglitz, B., Grabbe, C., Franz-Wachtel, M., van Wijk, S. J. L., Goswami, P., Nagy, V., Terzic, J., et al. (2011) · Nature · doi:10.1038/nature09814 · Cited by 745
Van den Brande, J. M. H., Braat, H., van den Brink, G. R., Versteeg, H. H., Bauer, C. A., Hoedemaeker, I., van Montfrans, C., Hommes, D. W., Peppelenbosch, M. P., & van Deventer, S. J. H. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00382-2 · Cited by 723
Tumour necrosis factors α and β inhibit virus replication and synergize with interferons
Wong, G. H. W., & Goeddel, D. V. (1986) · Nature · doi:10.1038/323819a0 · Cited by 713
The inflammasome: a danger sensing complex triggering innate immunity
Pétrilli, V., Dostert, C., Muruve, D. A., & Tschopp, J. (2007) · Current Opinion in Immunology · doi:10.1016/j.coi.2007.09.002 · Cited by 700
Scallon, B. (1995) · Cytokine · doi:10.1006/cyto.1995.0029 · Cited by 675
Ritchlin, C., Rahman, P., Kavanaugh, A., McInnes, I. B., Puig, L., Li, S., Wang, Y., Shen, Y.-K., Doyle, M. K., Mendelsohn, A. M., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204655 · Cited by 662
Yoo, D. H., Hrycaj, P., Miranda, P., Ramiterre, E., Piotrowski, M., Shevchuk, S., Kovalenko, V., Prodanovic, N., Abello-Banfi, M., Gutierrez-Ureña, S., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-203090 · Cited by 654
Vilcek, J., Palombella, V. J., Henriksen-DeStefano, D., Swenson, C., Feinman, R., Hirai, M., & Tsujimoto, M. (1986) · The Journal of experimental medicine · doi:10.1084/jem.163.3.632 · Cited by 640
Tubach, F., Salmon, D., Ravaud, P., Allanore, Y., Goupille, P., Bréban, M., Pallot‐Prades, B., Pouplin, S., Sacchi, A., Chichemanian, R. M., et al. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24632 · Cited by 632
Molecular Cloning of the Complementary DNA for Human Tumor Necrosis Factor
Wang, A. M., Creasey, A. A., Ladner, M. B., Lin, L. S., Strickler, J., Van Arsdell, J. N., Yamamoto, R., & Mark, D. F. (1985) · Science · doi:10.1126/science.3856324 · Cited by 622
Small-Molecule Inhibition of TNF-α
He, M. M., Smith, A. S., Oslob, J. D., Flanagan, W. M., Braisted, A. C., Whitty, A., Cancilla, M. T., Wang, J., Lugovskoy, A. A., Yoburn, J. C., et al. (2005) · Science · doi:10.1126/science.1116304 · Cited by 620
van de Putte, L. B. A., Atkins, C., Malaise, M., Sany, J., Russell, A. S., van Riel, P. L. C. M., Settas, L., Bijlsma, J. W., Todesco, S., Dougados, M., et al. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.013052 · Cited by 617
Teachey, D. T., Rheingold, S. R., Maude, S. L., Zugmaier, G., Barrett, D. M., Seif, A. E., Nichols, K. E., Suppa, E. K., Kalos, M., Berg, R. A., et al. (2013) · Blood · doi:10.1182/blood-2013-02-485623 · Cited by 613
SHARPIN is a component of the NF-κB-activating linear ubiquitin chain assembly complex
Tokunaga, F., Nakagawa, T., Nakahara, M., Saeki, Y., Taniguchi, M., Sakata, S.-I., Tanaka, K., Nakano, H., & Iwai, K. (2011) · Nature · doi:10.1038/nature09815 · Cited by 609
Park, W., Hrycaj, P., Jeka, S., Kovalenko, V., Lysenko, G., Miranda, P., Mikazane, H., Gutierrez-Ureña, S., Lim, M., Lee, Y.-A., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-203091 · Cited by 606
Zarnegar, B. J., Wang, Y., Mahoney, D. J., Dempsey, P. W., Cheung, H. H., He, J., Shiba, T., Yang, X., Yeh, W.-C., Mak, T. W., et al. (2008) · Nature Immunology · doi:10.1038/ni.1676 · Cited by 604
Fas- and Tumor Necrosis Factor-induced Apoptosis Is Inhibited by the Poxvirus crmA Gene Product
Tewari, M., & Dixit, V. M. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.7.3255 · Cited by 596
Kohase, M., Henriksen-DeStefano, D., May, L. T., Vilček, J., & Sehgal, P. B. (1986) · Cell · doi:10.1016/0092-8674(86)90780-4 · Cited by 567
Tartaglia, L. A., Pennica, D., & Goeddel, D. V. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)46661-0 · Cited by 562
A JNK-Dependent Pathway Is Required for TNFα-Induced Apoptosis
Deng, Y., Ren, X., Yang, L., Lin, Y., & Wu, X. (2003) · Cell · doi:10.1016/s0092-8674(03)00757-8 · Cited by 559
PEGylated antibodies and antibody fragments for improved therapy: a review
Chapman, A. P. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00026-1 · Cited by 556
Song, H. Y., Régnier, C. H., Kirschning, C. J., Goeddel, D. V., & Rothe, M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.18.9792 · Cited by 553
Heiss, M. M., Murawa, P., Koralewski, P., Kutarska, E., Kolesnik, O. O., Ivanchenko, V. V., Dudnichenko, A. S., Aleknaviciene, B., Razbadauskas, A., Gore, M., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25423 · Cited by 549
Chen, X., Bäumel, M., Männel, D. N., Howard, O. M. Z., & Oppenheim, J. J. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.1.154 · Cited by 548
van der Heijde, D., Klareskog, L., Rodriguez‐Valverde, V., Codreanu, C., Bolosiu, H., Melo‐Gomes, J., Tornero‐Molina, J., Wajdula, J., Pedersen, R., Fatenejad, S., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21655 · Cited by 535
Smolen, J. S., Kay, J., Doyle, M. K., Landewé, R., Matteson, E. L., Wollenhaupt, J., Gaylis, N., Murphy, F. T., Neal, J. S., Zhou, Y., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60506-7 · Cited by 526
Nie, H., Zheng, Y., Li, R., Guo, T. B., He, D., Fang, L., Liu, X., Xiao, L., Chen, X., Wan, B., et al. (2013) · Nature Medicine · doi:10.1038/nm.3085 · Cited by 515
Nesbitt, A., Fossati, G., Bergin, M., Stephens, P., Stephens, S., Foulkes, R., Brown, D., Robinson, M., & Bourne, T. (2007) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20225 · Cited by 477
PHARMACOKINETICS AND PHARMACODYNAMICS OF CURCUMIN
Sharma, R. A., Steward, W. P., & Gescher, A. J. (2007) · ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY · doi:10.1007/978-0-387-46401-5_20 · Cited by 476
Liao, G., Zhang, M., Harhaj, E. W., & Sun, S.-C. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403286200 · Cited by 465
Chan, F. K.-M., Shisler, J., Bixby, J. G., Felices, M., Zheng, L., Appel, M., Orenstein, J., Moss, B., & Lenardo, M. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305633200 · Cited by 464
Cloning and expression in Escherichia coli of the gene for human tumour necrosis factor
Shirai, T., Yamaguchi, H., Ito, H., Todd, C. W., & Wallace, R. B. (1985) · Nature · doi:10.1038/313803a0 · Cited by 459
Williamson, B. D., Carswell, E. A., Rubin, B. Y., Prendergast, J. S., & Old, L. J. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.17.5397 · Cited by 456
Case Reports of Heart Failure after Therapy with a Tumor Necrosis Factor Antagonist
Kwon, H. J., Cot, T. R., Cuffe, M. S., Kramer, J. M., & Braun, M. M. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-10-200305200-00008 · Cited by 455
Waage, A., Halstensen, A., Shalaby, R., Brandtzaeg, P., Kierulf, P., & Espevik, T. (1989) · The Journal of experimental medicine · doi:10.1084/jem.170.6.1859 · Cited by 454
Activation of SAPK/JNK by TNF Receptor 1 Through a Noncytotoxic TRAF2-Dependent Pathway
Natoli, G., Costanzo, A., Ianni, A., Templeton, D. J., Woodgett, J. R., Balsano, C., & Levrero, M. (1997) · Science · doi:10.1126/science.275.5297.200 · Cited by 452
Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis
van Schouwenburg, P. A., Rispens, T., & Wolbink, G. J. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.4 · Cited by 438
Billioud, V., Sandborn, W. J., & Peyrin-Biroulet, L. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.60 · Cited by 433
Hong, J. (2004) · Carcinogenesis · doi:10.1093/carcin/bgh165 · Cited by 432
Prevention of Constitutive TNF Receptor 1 Signaling by Silencer of Death Domains
Jiang, Y., Woronicz, J. D., Liu, W., & Goeddel, D. V. (1999) · Science · doi:10.1126/science.283.5401.543 · Cited by 417
Garcês, S., Demengeot, J., & Benito-Garcia, E. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202220 · Cited by 411
Dinarello, C. A. (1991) · Journal of Infectious Diseases · doi:10.1093/infdis/163.6.1177 · Cited by 397
Atreya, R., Neumann, H., Neufert, C., Waldner, M. J., Billmeier, U., Zopf, Y., Willma, M., App, C., Münster, T., Kessler, H., et al. (2014) · Nature Medicine · doi:10.1038/nm.3462 · Cited by 392 · cited 4×
“Of particular interest, however, is a 2014 report demonstrating that expression of colonic membrane TNF is a possible identifier of anti-TNF therapeutic responders [287].”
BackgroundMethodInfluentialAnti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis
Taylor, P. C., & Feldmann, M. (2009) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.181 · Cited by 389
Purification and physico-chemical characterization of rabbit tumor necrosis factor.
Ruff, M. R., & Gifford, G. E. (1980) · The Journal of Immunology · doi:10.4049/jimmunol.125.4.1671 · Cited by 385
FAN, a Novel WD-Repeat Protein, Couples the p55 TNF-Receptor to Neutral Sphingomyelinase
Adam-Klages, S., Adam, D., Wiegmann, K., Struve, S., Kolanus, W., Schneider-Mergener, J., & Krönke, M. (1996) · Cell · doi:10.1016/s0092-8674(00)80169-5 · Cited by 381
Therapeutic Inflammatory Monocyte Modulation Using Immune-Modifying Microparticles
Getts, D. R., Terry, R. L., Getts, M. T., Deffrasnes, C., Müller, M., van Vreden, C., Ashhurst, T. M., Chami, B., McCarthy, D., Wu, H., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007563 · Cited by 378
Blockade of TNF-α rapidly inhibits pain responses in the central nervous system
Hess, A., Axmann, R., Rech, J., Finzel, S., Heindl, C., Kreitz, S., Sergeeva, M., Saake, M., Garcia, M., Kollias, G., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011774108 · Cited by 356
Komiyama, T., Ray, C. A., Pickup, D. J., Howard, A. D., Thornberry, N. A., Peterson, E. P., & Salvesen, G. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)32171-3 · Cited by 351
Sokolove, J., Zhao, X., Chandra, P. E., & Robinson, W. H. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30081 · Cited by 340
Tumor necrosis factor's cytotoxic activity is signaled by the p55 TNF receptor
Tartaglia, L. A., Rothe, M., Hu, Y.-F., & Goeddel, D. V. (1993) · Cell · doi:10.1016/0092-8674(93)90222-c · Cited by 339
Nanda, K. S., Cheifetz, A. S., & Moss, A. C. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.363 · Cited by 336
Cathepsin D links TNF-induced acid sphingomyelinase to Bid-mediated caspase-9 and -3 activation
Heinrich, M., Neumeyer, J., Jakob, M., Hallas, C., Tchikov, V, Winoto-Morbach, S., Wickel, M., Schneider-Brachert, W., Trauzold, A., Hethke, A., et al. (2004) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401382 · Cited by 332
Haranaka, K., Satomi, N., & Sakurai, A. (1984) · International Journal of Cancer · doi:10.1002/ijc.2910340219 · Cited by 311
Kim, G.-Y., Kim, K.-H., Lee, S.-H., Yoon, M.-S., Lee, H.-J., Moon, D.-O., Lee, C.-M., Ahn, S.-C., Park, Y. C., & Park, Y.-M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.12.8116 · Cited by 306
Fibbe, C., Layer, P., Keller, J., Strate, U., Emmermann, A., & Zornig, C. (2001) · Gastroenterology · doi:10.1053/gast.2001.25486 · Cited by 303
Interferon-gamma enhances expression of cellular receptors for tumor necrosis factor.
Tsujimoto, M., Yip, Y. K., & Vilček, J. (1986) · The Journal of Immunology · doi:10.4049/jimmunol.136.7.2441 · Cited by 301
Eissner, G., Kolch, W., & Scheurich, P. (2004) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2004.03.011 · Cited by 298
Contact with T cells modulates monocyte IL-10 production: role of T cell membrane TNF-alpha
Parry, S. L., Sebbag, M., Feldmann, M., & Brennan, F. M. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.8.3673 · Cited by 295
Depressive-like behavior induced by tumor necrosis factor-α in mice
Kaster, M. P., Gadotti, V. M., Calixto, J. B., Santos, A. R. S., & Rodrigues, A. L. S. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.018 · Cited by 294
Endotoxin, tumor necrosis factor-α and interleukin 1 induce interleukin 6 production in vivo
Shalaby, M. R., Waage, A., Aarden, L., & Espevik, T. (1989) · Clinical Immunology and Immunopathology · doi:10.1016/0090-1229(89)90010-x · Cited by 294
Westwick, J. K., Weitzel, C., Minden, A., Karin, M., & Brenner, D. A. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47207-9 · Cited by 293
How tumour necrosis factor blockers interfere with tuberculosis immunity
Harris, J., & Keane, J. (2010) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2010.04146.x · Cited by 291
Zhang, Y. H., Lin, J. X., Yip, Y. K., & Vilcek, J. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.18.6802 · Cited by 286
Sphingolipids in inflammation: pathological implications and potential therapeutic targets
Nixon, G. F. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00281.x · Cited by 285
Transcriptional Control of the TNF Gene
Falvo, J. V., Tsytsykova, A. V., & Goldfeld, A. E. (2010) · Current Directions in Autoimmunity · doi:10.1159/000289196 · Cited by 281
Fransen, L., van der Heyden, J., Ruysschaert, R., & Fiers, W. (1986) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(86)90107-0 · Cited by 281
Skelly, D. T., Hennessy, E., Dansereau, M.-A., & Cunningham, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069123 · Cited by 274
Sedger, L. M., Shows, D. M., Blanton, R. A., Peschon, J. J., Goodwin, R. G., Cosman, D. J., & Wiley, S. R. (1999) · PubMed · Cited by 270
Self-citationMitoma, H., Horiuchi, T., Hatta, N., Tsukamoto, H., Harashima, S.-I., Kikuchi, Y., Otsuka, J., Okamura, S., Fujita, S., & Harada, M. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.11.060 · Cited by 270
Fürst, R., & Zündorf, I. (2014) · Mediators of Inflammation · doi:10.1155/2014/146832 · Cited by 269
Molecular cloning of mouse tumour necrosis factor cDNA and its eukaryotic expression
Fransen, L., Mūller, R., Marmenout, A., Tavernier, J., Heyden, J. V. D., Kawashima, E., Chollet, A., Tizard, R., Heuverswyn, H. V., Vliet, A. V., et al. (1985) · Nucleic Acids Research · doi:10.1093/nar/13.12.4417 · Cited by 263
Trinchieri, G., Kobayashi, M., Rosen, M., Loudon, R., Murphy, M., & Perussia, B. (1986) · The Journal of experimental medicine · doi:10.1084/jem.164.4.1206 · Cited by 253
Takashiba, S., Van Dyke, T. E., Amar, S., Murayama, Y., Soskolne, A. W., & Shapira, L. (1999) · Infection and Immunity · doi:10.1128/iai.67.11.5573-5578.1999 · Cited by 253
TNFα Signaling in Depression and Anxiety: Behavioral Consequences of Individual Receptor Targeting
Simen, B. B., Duman, C. H., Simen, A. A., & Duman, R. S. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.10.013 · Cited by 250
Manipulation of the nuclear factor-κB pathway and the innate immune response by viruses
Hiscott, J., Nguyen, T.-L. A., Arguello, M., Nakhaei, P., & Paz, S. (2006) · Oncogene · doi:10.1038/sj.onc.1209941 · Cited by 247
Activation of the NF-κB pathway by Caspase 8 and its homologs
Chaudhary, P. M., Eby, M. T., Jasmin, A., Kumar, A., Liu, L., & Hood, L. (2000) · Oncogene · doi:10.1038/sj.onc.1203812 · Cited by 242
Vince, J. E., Pantaki, D., Feltham, R., Mace, P. D., Cordier, S. M., Schmukle, A. C., Davidson, A. J., Callus, B. A., Wong, W. W.-L., Gentle, I. E., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.072256 · Cited by 241
Effect of tumor necrosis factor alpha on mitogen-activated human B cells.
Kehrl, J. H., Miller, A., & Fauci, A. S. (1987) · The Journal of experimental medicine · doi:10.1084/jem.166.3.786 · Cited by 236
Etanercept for the Treatment of Rheumatoid Arthritis
Zhao, S., Mysler, E., & Moots, R. J. (2018) · Immunotherapy · doi:10.2217/imt-2017-0155 · Cited by 236
Kataoka, T., & Tschopp, J. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.7.2627-2636.2004 · Cited by 235
Furst, D. E., Wallis, R., Broder, M., & Beenhouwer, D. O. (2006) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2006.02.001 · Cited by 233
The roles of TNF in brain dysfunction and disease
Clark, I. A., Alleva, L. M., & Vissel, B. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.08.007 · Cited by 232
Sedger, L. M., Shows, D. M., Blanton, R. A., Peschon, J. J., Goodwin, R. G., Cosman, D., & Wiley, S. R. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.2.920 · Cited by 232
Self-citationLobito, A. A., Kimberley, F. C., Muppidi, J. R., Komarow, H., Jackson, A. J., Hull, K. M., Kastner, D. L., Screaton, G. R., & Siegel, R. M. (2006) · Blood · doi:10.1182/blood-2005-11-006783 · Cited by 229
Siegel, S. A., Shealy, D. J., Nakada, M. T., Le, J., Woulfe, D. S., Probert, L., Kollias, G., Ghrayeb, J., Vilcek, J., & Daddona, P. E. (1995) · Cytokine · doi:10.1006/cyto.1995.1003 · Cited by 222
Feinberg, B., Kurzrock, R., Talpaz, M., Blick, M., Saks, S., & Gutterman, J. U. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.8.1328 · Cited by 221
Vos, A. C. W., Wildenberg, M. E., Duijvestein, M., Verhaar, A. P., van den Brink, G. R., & Hommes, D. W. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.10.008 · Cited by 218
Yamaguchi, Y., Tsumura, H., Miwa, M., & Inaba, K. (1997) · STEM CELLS · doi:10.1002/stem.150144 · Cited by 215
BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies
Ding, T., Ledingham, J., Luqmani, R., Westlake, S., Hyrich, K., Lunt, M., Kiely, P., Bukhari, M., Abernethy, R., Bosworth, A., et al. (2010) · Rheumatology · doi:10.1093/rheumatology/keq249a · Cited by 215
Inflammatory mechanisms in major depressive disorder
Raedler, T. J. (2011) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e32834b9db6 · Cited by 213
Jelinek, D. F., & Lipsky, P. E. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.139.9.2970 · Cited by 207
Schütze, S., Machleidt, T., & Krönke, M. (1994) · Journal of Leukocyte Biology · doi:10.1002/jlb.56.5.533 · Cited by 205
Tweedie, D., Ferguson, R. A., Fishman, K., Frankola, K. A., Van Praag, H., Holloway, H. W., Luo, W., Li, Y., Caracciolo, L., Russo, I., et al. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-106 · Cited by 204
van Schouwenburg, P. A., van de Stadt, L. A., de Jong, R. N., van Buren, E. E. L., Kruithof, S., de Groot, E., Hart, M., van Ham, S. M., Rispens, T., Aarden, L., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-201445 · Cited by 203
Cell cycle-specific effects of tumor necrosis factor.
Darżynkiewicz, Z., Williamson, B., Carswell, E. A., & Old, L. J. (1984) · PubMed · Cited by 202
Mathews, R. J., Robinson, J. I., Battellino, M., Wong, C., Taylor, J. C., Eyre, S., Churchman, S. M., Wilson, A. G., Isaacs, J. D., Hyrich, K., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203276 · Cited by 201
Self-citationTumor necrosis factor blockade and the risk of viral infection
Kim, S. Y., & Solomon, D. H. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.279 · Cited by 197
Listing, J., Strangfeld, A., Kekow, J., Schneider, M., Kapelle, A., Wassenberg, S., & Zink, A. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23281 · Cited by 195
Watts, A. D. (1999) · The EMBO Journal · doi:10.1093/emboj/18.8.2119 · Cited by 195
Eissner, G., Kirchner, S., Lindner, H., Kolch, W., Janosch, P., Grell, M., Scheurich, P., Andreesen, R., & Holler, E. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.12.6193 · Cited by 193
Tsai, E. Y., Yie, J., Thanos, D., & Goldfeld, A. E. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.10.5232 · Cited by 188
Di Sabatino, A. (2004) · Gut · doi:10.1136/gut.53.1.70 · Cited by 186
Demyelination and other neurological adverse events after anti-TNF therapy
Kaltsonoudis, E., Voulgari, P. V., Konitsiotis, S., & Drosos, A. A. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2013.09.002 · Cited by 184
Identity of differentiation inducing factor and tumour necrosis factor
Takeda, K., Iwamoto, S., Sugimoto, H., Takuma, T., Kawatani, N., Noda, M., Masaki, A., Morise, H., Arimura, H., & Konno, K. (1986) · Nature · doi:10.1038/323338a0 · Cited by 182
Kang, G., Kong, P.-J., Yuh, Y.-J., Lim, S.-Y., Yim, S.-V., Chun, W., & Kim, S.-S. (2004) · Journal of Pharmacological Sciences · doi:10.1254/jphs.94.325 · Cited by 180
Patient Perceptions concerning Pain Management in the Treatment of Rheumatoid Arthritis
Taylor, P., Manger, B., Alvaro-Gracia, J., Johnstone, R., Gomez-Reino, J., Eberhardt, E., Wolfe, F., Schwartzman, S., Furfaro, N., & Kavanaugh, A. (2010) · Journal of International Medical Research · doi:10.1177/147323001003800402 · Cited by 180
Zhang, T., Kruys, V., Huez, G., & Gueydan, C. (2002) · Biochemical Society Transactions · doi:10.1042/bst0300952 · Cited by 178
Ray, B., Bisht, S., Maitra, A., Maitra, A., & Lahiri, D. K. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-101374 · Cited by 177
Systemic use of tumor necrosis factor alpha as an anticancer agent
Roberts, N. J., Zhou, S., Diaz, L. A., & Holdhoff, M. (2011) · Oncotarget · doi:10.18632/oncotarget.344 · Cited by 177
Human papilloma virus is associated with breast cancer
Heng, B., Glenn, W. K., Ye, Y., Tran, B., Delprado, W., Lutze-Mann, L., Whitaker, N. J., & Lawson, J. S. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605282 · Cited by 176
Tuohy, V. K., Yu, M., Yin, L., Kawczak, J. A., Johnson, J. M., Mathisen, P. M., Weinstock-Guttinan, B., & Kinkel, R. P. (1998) · Immunological Reviews · doi:10.1111/j.1600-065x.1998.tb01211.x · Cited by 174
Curcumin and neurodegenerative diseases
Monroy, A., Lithgow, G. J., & Alavez, S. (2013) · BioFactors · doi:10.1002/biof.1063 · Cited by 172
Targeting T cells to tumor cells using bispecific antibodies
Frankel, S. R., & Baeuerle, P. A. (2013) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2013.03.029 · Cited by 166
Schoultz, I., Verma, D., Halfvarsson, J., Törkvist, L., Fredrikson, M., Sjöqvist, U., Lördal, M., Tysk, C., Lerm, M., Söderkvist, P., et al. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.29 · Cited by 166
Aversa, G., Punnonen, J., & de Vries, J. E. (1993) · The Journal of Experimental Medicine · doi:10.1084/jem.177.6.1575 · Cited by 165
Receptor-Mediated Endocytosis and Brain Delivery of Therapeutic Biologics
Xiao, G., & Gan, L.-S. (2013) · International Journal of Cell Biology · doi:10.1155/2013/703545 · Cited by 163
Cell-Penetrating Peptide-Mediated Therapeutic Molecule Delivery into the Central Nervous System
Zou, L.-L., Ma, J.-L., Wang, T., Yang, T.-B., & Liu, C.-B. (2013) · Current Neuropharmacology · doi:10.2174/1570159x11311020006 · Cited by 163
Tripodo, C., Iannitto, E., Florena, A. M., Pucillo, C. E., Piccaluga, P. P., Franco, V., & Pileri, S. A. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.169 · Cited by 163
Mammalian initiator apoptotic caspases
Ho, P., & Hawkins, C. J. (2005) · The FEBS Journal · doi:10.1111/j.1742-4658.2005.04966.x · Cited by 162
den Broeder, A. A., Joosten, L. A. B., Saxne, T., Heinegård, D., Fenner, H., Miltenburg, A. M. M., Frasa, W. L. H., van Tits, L. J., Buurman, W. A., van Riel, P. L. C. M., et al. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.4.311 · Cited by 161
Factors predicting outcome of rheumatoid arthritis: results of a followup study.
van Zeben, D., Hazes, J. M. W., Zwinderman, A. H., Vandenbroucke, J. P., & Fc, B. (1993) · PubMed · Cited by 161
George, A., Marziniak, M., Schäfers, M., Toyka, K. V., & Sommer, C. (2000) · Pain · doi:10.1016/s0304-3959(00)00333-x · Cited by 160
Majumdar, S., Lamothe, B., & Aggarwal, B. B. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.6.2644 · Cited by 160
Doggui, S., Sahni, J. K., Arseneault, M., Dao, L. H., & Ramassamy, C. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-112141 · Cited by 159
Zhu, X., Li, Q., Chang, R., Yang, D., Song, Z., Guo, Q., & Huang, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091303 · Cited by 159
Carter, P. H., Scherle, P., Muckelbauer, J. A., Voss, M. E., Liu, R., Thompson, L. A., Tebben, A. J., Solomon, K. A., Lo, Y. C., Li, Z., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.211178398 · Cited by 159
Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases
Taylor, P. C. (2010) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2010.01.005 · Cited by 155
Sandborn, W. J., Feagan, B. G., Radford‐Smith, G. L., Kovacs, A., Enns, R., Innes, A., & Patel, J. (2004) · Gut · doi:10.1136/gut.2003.035253 · Cited by 154
Plant, D., Bowes, J., Potter, C., Hyrich, K. L., Morgan, A. W., Wilson, A. G., Isaacs, J. D., British Society for Rheumatology Biologics Register, & Barton, A. C. (2010) · Arthritis & Rheumatism · doi:10.1002/art.30130 · Cited by 153
Bulua, A. C., Mogul, D. B., Aksentijevich, I. A., Singh, H., He, D. Y., Muenz, L. R., Ward, M. M., Yarboro, C. H., Kastner, D. L., Siegel, R. M., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.33416 · Cited by 150
Schwabe, R. F., Uchinami, H., Qian, T., Bennett, B. L., Lemasters, J. J., & Brenner, D. A. (2004) · The FASEB Journal · doi:10.1096/fj.03-0771fje · Cited by 150
Phase I clinical trial of recombinant human tumor necrosis factor
Creaven, P. J., Plager, J., Dupéré, S., Huben, R., Takita, H., Mittelman, A., & Proefrock, A. (1987) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00253968 · Cited by 148
Smyth, M. J., Kelly, J. M., Baxter, A. G., Körner, H., & Sedgwick, J. D. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.9.1611 · Cited by 148
Identification of human papillomavirus DNA gene sequences in human breast cancer
Kan, C.-Y., Iacopetta, B. J., Lawson, J. S., & Whitaker, N. J. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602778 · Cited by 144
Tumor Necrosis Factor Blockers Influence Macrophage Responses toMycobacterium tuberculosis
Harris, J., Hope, J. C., & Keane, J. (2008) · The Journal of Infectious Diseases · doi:10.1086/593174 · Cited by 144
Inflammatory demyelinating events following treatment with anti-tumor necrosis factor
Fromont, A., Seze, J. D., Fleury, M., Maillefert, J.-F., & Moreau, T. (2008) · Cytokine · doi:10.1016/j.cyto.2008.11.002 · Cited by 136
Deng, G., Zheng, L., Chan, F. K.-M., & Lenardo, M. J. (2005) · Nature Medicine · doi:10.1038/nm1304 · Cited by 135
Curcumin is a potent modulator of microglial gene expression and migration
Karlstetter, M., der Lippe, E., Walczak, Y., Moehle, C., Aslanidis, A., Mirza, M., & Langmann, T. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-125 · Cited by 134
Successful Antidepressant Therapy Restores the Disturbed Interplay Between TNF-α System and HPA Axis
Himmerich, H., Binder, E. B., Kunzel, H. E., Schuld, A., Lucae, S., Uhr, M., Pollmächer, T., Holsboer, F., & Ising, M. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.03.075 · Cited by 134
Razani, B., Zarnegar, B. J., Ytterberg, A. J., Shiba, T. L., Dempsey, P. W., Ware, C. F., Loo, J. A., & Cheng, G. (2010) · Science Signaling · doi:10.1126/scisignal.2000778 · Cited by 127
Ceramide as an Activator Lipid of Cathepsin D
Heinrich, M., Wickel, M., Winoto‐Morbach, S., Schneider‐Brachert, W., Weber, T., Brunner, J., Säftig, P., Peters, C., Krönke, M., & Schütze, S. (2006) · Kluwer Academic Publishers eBooks · doi:10.1007/0-306-46826-3_33 · Cited by 126
Rebelo, S. L., Bainbridge, S. E., Kashipaz, M. R. A., Radford, P. M., Powell, R. J., Todd, I., & Tighe, P. J. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21964 · Cited by 122
Signaling for survival and apoptosis in the immune system.
Mak, T. W., & Yeh, W. (2002) · Arthritis Research · doi:10.1186/ar569 · Cited by 121
Peripheral inflammation is associated with remote global gene expression changes in the brain
Thomson, C. A., McColl, A., Cavanagh, J., & Graham, G. J. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-73 · Cited by 121
Takasaki, W., Kajino, Y., Kajino, K., Murali, R., & Greene, M. I. (1997) · Nature Biotechnology · doi:10.1038/nbt1197-1266 · Cited by 121
Antiviral Activity of Tumor Necrosis Factor (TNF) Is Mediated via p55 and p75 TNF Receptors
Ruby, J. C., Bluethmann, H., & Peschon, J. J. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.9.1591 · Cited by 121
Brouckaert, P., Spriggs, D. R., Demetri, G. D., Kufe, D. W., & Fiers, W. (1989) · The Journal of Experimental Medicine · doi:10.1084/jem.169.6.2257 · Cited by 120
Hueber, W., Tomooka, B. H., Batliwalla, F., Li, W., Monach, P. A., Tibshirani, R. J., van Vollenhoven, R., Lampa, J., Saito, K., Tanaka, Y., et al. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2706 · Cited by 118
Function and Regulation of Tumor Necrosis Factor Receptor Type 2
Carpentier, I., Coornaert, B., & Beyaert, R. (2004) · Current Medicinal Chemistry · doi:10.2174/0929867043364694 · Cited by 117
Extrinsic and intrinsic control of macrophage inflammatory responses
Cohen, H. B., & Mosser, D. M. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.0413236 · Cited by 114
Research works printed but not linked: 65
- Matthews, 1980, Tumour-necrosis factor from the rabbit. IV. Purification and chemical characterization, Br J Cancer, 42, 416, 10.1038/bjc.1980.253 · doi:10.1038/bjc.1980.253
- Matthews, 1979, Tumour-necrosis factor from the rabbit. III. Relationship to interferons, Br J Cancer, 40, 534, 10.1038/bjc.1979.218 · doi:10.1038/bjc.1979.218
- Prince, 1982, Inhibition of L-cell growth in agarose (ILGA): a simple inexpensive method for the detection and quantitation of factors inhibiting tumor cell growth, J Immunol Methods, 48, 367, 10.1016/0022-1759(82)90337-4 · doi:10.1016/0022-1759(82)90337-4
- Bloksma, 1983, Antitumour activity of endotoxin, concanavalin A and poly I: C and their ability to elicit tumour necrosis factor, cytostatic factors, and interferon in vivo, Cancer Immunol Immunother, 16, 35, 10.1007/BF00199903 · doi:10.1007/bf00199903
- English, 1991, Differential regulation of lymphotoxin and tumor necrosis factor genes in human T lymphocytes, J Biol Chem, 266, 7108, 10.1016/S0021-9258(20)89617-3 · doi:10.1016/s0021-9258(20)89617-3
- Turner, 1988, Comparison of patterns of expression of tumour necrosis factor, lymphotoxin and interleukin-6 mRNA, Biochem Biophys Res Commun, 153, 1144, 10.1016/S0006-291X(88)81347-0 · doi:10.1016/s0006-291x(88)81347-0
- Ziegler-Heitbrock, 1986, Tumor necrosis factor as effector molecule in monocyte mediated cytotoxicity, Cancer Res, 46, 5947
- Haranaka, 1987, Antitumour effects of tumour necrosis factor: cytotoxic or necrotizing activity and its mechanism, Ciba Found Symp, 131, 140
- Schwartz, 1989, A phase I trial of recombinant tumor necrosis factor (rTNF) administered by continuous intravenous infusion in patients with disseminated malignancy, Biotherapy, 1, 207, 10.1007/BF02170889 · doi:10.1007/bf02170889
- Zamkoff, 1989, A phase I trial of subcutaneously administered recombination tumor necrosis factor to patients with advanced malignancy, J Biol Response Mod, 8, 539
- Negrier, 1991, Phase I trial of recombinant interleukin-2 followed by recombinant tumor necrosis factor in patients with metastatic cancer, J Immunother, 11, 93, 10.1097/00002371-199202000-00003 · doi:10.1097/00002371-199202000-00003
- Xin, 2006, Dual regulation of soluble tumor necrosis factor-alpha induced activation of human monocytic cells via modulating transmembrane TNF-alpha-mediated ‘reverse signaling’, Int J Mol Med, 18, 885
- Austgulen, 1986, Role of monocyte cytotoxic factor in cytolysis of actinomycin D-treated WEHI 164 cells mediated by freshly isolated human adherent mononuclear blood cells, Cancer Res, 46, 4566
- Munker, 1987, In vitro action of tumor necrosis factor on myeloid leukemia cells, Blood, 69, 1102, 10.1182/blood.V69.4.1102.1102 · doi:10.1182/blood.v69.4.1102.1102
- Suyama, 1985, Effects of murine tumor necrosis factor on friend erythroleukemic cells, Exp Cell Biol, 53, 85
- Sedger, 2005, Viral inhibition of tumour necrosis factor-α and TNFα and TNF-receptor induced apoptosis and inflammation, Curr Med Chem Anti Inflam Anti Aller, 4, 597, 10.2174/156801405774933124 · doi:10.2174/156801405774933124
- Warzocha, 1995, Mechanisms of action of the tumor necrosis factor and lymphotoxin ligand-receptor system, Eur Cytokine Netw, 6, 83
- Fiers, 1987, Structure-function relationship of tumour necrosis factor and its mechanism of action, Ciba Found Symp, 131, 109
- Boecke, 2012, Factor associated with neutral sphingomyelinase activity mediates navigational capacity of leukocytes responding to wounds and infection: live imaging studies in zebrafish larvae, J Immunol, 189, 1559, 10.4049/jimmunol.1102207 · DOI
- Christoforidis, 2003, Isolated limb perfusion: distinct tourniquet and tumor necrosis factor effects on the early hemodynamic response, Arch Surg, 138, 17, 10.1001/archsurg.138.1.17 · doi:10.1001/archsurg.138.1.17
- Yousaf, 2005, Tumor necrosis factor receptor I from patients with tumor necrosis factor receptor-associated periodic syndrome interacts with wild-type tumor necrosis factor receptor I and induces ligand-independent NF-κB activation, Arthritis Rheum, 52, 2906, 10.1002/art.21268 · DOI
- Upton, 1991, Myxoma virus expresses a secreted protein with homology to the tumor necrosis factor receptor gene family that contributes to viral virulence, Virology, 184, 370, 10.1016/0042-6822(91)90853-4 · doi:10.1016/0042-6822(91)90853-4
- Hutas, 2010, Golimumab as the first monthly subcutaneous fully human anti-TNF-α antibody in the treatment of inflammatory arthropathies, Immunotherapy, 2, 453, 10.2217/imt.10.34 · doi:10.2217/imt.10.34
- Meroni, 2014, Tumour necrosis factor-α antagonists in the treatment of Rheumatoid arthritis: an immunological perspective, BioDrugs, 28, S5, 10.1007/s40259-013-0063-0 · DOI
- Bendele, 1999, Effects of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) alone and in combination with methotrexate in adjuvant arthritic rats, Clin Exp Rheumatol, 17, 553
- McComb, 1999, Antiarthritic activity of soluble tumor necrosis factor receptor type I forms in adjuvant arthritis: correlation of plasma levels with efficacy, J Rheumatol, 26, 1347
- Trinchard-Lugan, 2001, Safety, pharmakinetics and pharmacodynamics of recombinant human tumour necrosis factor binding proteins-1 (Onercept) injected by intravenous, intramuscular and subcutaneous routes into healthy volunteers, Eur Cytokine Netw, 12, 391
- Kay, 2013, Biosimilars to treat inflammatory arthritis: the challenge of proving identity, Ann Rheum Dis, 72, 1589, 10.1136/annrheumdis-2012-203198 · doi:10.1136/annrheumdis-2012-203198
- Scheinberg, 2012, The advent of biosimilar therapies in rheumatology-“O brave new world”, Nat Rev Rheumatol, 8, 430, 10.1038/nrrheum.2012.84 · doi:10.1038/nrrheum.2012.84
- Leck, 1962, Incidence of malformations since the introduction of thalidomide, Br Med J, 2, 16, 10.1136/bmj.2.5296.16 · doi:10.1136/bmj.2.5296.16
- Ringheanu, 2004, Effects of infliximab on apoptosis and reverse signaling of monocytes from healthy individuals and patients with Crohn's disease, Inflamm Bowel Dis, 10, 801, 10.1097/00054725-200411000-00015 · doi:10.1097/00054725-200411000-00015
- Xin, 2006, Dual regulation of soluble tumour necrosis factor-α inducing activation of human monocytic cells via modulation transmembrane TNFα-metiated “reverse signalling”, Int J Mol Med, 18, 885
- Mitoma, 2005, Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-α, Gastroenterology, 128, 376, 10.1053/j.gastro.2004.11.060 · DOI · Paper page
- Nestorov, 2005, Clinical pharmacokinetics of TNF antagonists: how do they differ?, Semin Arthritis Rheum, 34, 12, 10.1016/j.semarthrit.2005.01.004 · doi:10.1016/j.semarthrit.2005.01.004
- Steenholdt, 2012, Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn's disease, J Crohns Colitis, 6, 108, 10.1016/j.crohns.2011.08.001 · DOI
- Bracaglia, 2012, Safety and efficacy of etanercept in a cohort of patients with juvenile idiopathic arthritis under 4 years of age, J Rheumatol, 39, 1287, 10.3899/jrheum.111555 · doi:10.3899/jrheum.111555
- Li Gobbi, 2005, Pneumonitis caused by Legionella pneumoniae in a patient with rheumatoid arthritis treated with anti-TNF-alpha therapy (infliximab), J Clin Rheumatol, 11, 119, 10.1097/01.rhu.0000158527.20518.30 · doi:10.1097/01.rhu.0000158527.20518.30
- Mancini, 2007, Tuberculosis and Legionella pneumophila pneumonia in a patient receiving anti-tumour necrosis factor-α (anti-TNF-alpha) treatment, Clin Microbiol Infect, 13, 1036, 10.1111/j.1469-0691.2007.01796.x · doi:10.1111/j.1469-0691.2007.01796.x
- Lanternier, 2013, Incidence and risk factors of Legionella pneumophila pneumonia during anti-tumor necrosis factor therapy: a prospective French study, Chest, 144, 990, 10.1378/chest.12-2820 · doi:10.1378/chest.12-2820
- Hofmann, 2009, Fulminant legionellosis in two patients treated with infliximab for Crohn's disease: case series and literature review, Can J Gastroenterol, 23, 829, 10.1155/2009/836938 · doi:10.1155/2009/836938
- Kang, 2007, Adenoviral pneumonia during etanercept treatment in a patient with rheumatoid arthritis, Korean J Intern Med, 22, 63, 10.3904/kjim.2007.22.1.63 · doi:10.3904/kjim.2007.22.1.63
- Smith, 2002, Viral pneumonia as a serious complication of etanercept therapy, Ann Intern Med, 136, 174, 10.7326/0003-4819-136-2-200201150-00020 · doi:10.7326/0003-4819-136-2-200201150-00020
- Cantini, 2014, Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance, J Rheumatol Suppl, 91, 47, 10.3899/jrheum.140102 · doi:10.3899/jrheum.140102
- Navarra, 2014, Risk of tuberculosis with anti-tumour necrosis factor-α therapy: substantially higher number of patients at risk in Asia, Int J Rheum Dis, 17, 3, 10.1111/1756-185X.12188 · doi:10.1111/1756-185x.12188
- Glenn, 2012, Epstein–Barr virus, human papillomavirus and mouse mammary tumour virus as multiple viruses in breast cancer, PLoS One, 7, e48788, 10.1371/journal.pone.0048788 · doi:10.1371/journal.pone.0048788
- Mohan, 2001, Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides, Arthritis Rheum, 44, 2862, 10.1002/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W · doi:10.1002/1529-0131(200112)44:12<2862::aid-art474>3.0.co;2-w
- Tanno, 2006, New-onset demyelination induced by infliximab therapy in two rheumatoid arthritis patients, Clin Rheumatol, 25, 929, 10.1007/s10067-005-0097-x · doi:10.1007/s10067-005-0097-x
- Andreadou, 2013, Demyelinating disease following anti-TNFα treatment: a causal or coincidental association? Report of four cases and review of the literature, Case Rep Neurol Med, 2013, 671935
- Kaltsonoudis, 2014, Neurological adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study, Arthritis Res Ther, 16, R125, 10.1186/ar4582 · doi:10.1186/ar4582
- Ledingham, 2005, British thoracic society (BTS) recommendations for assessing risk and managing tuberculosis in patients due to start anti-TNF-{alpha} treatments, Rheumatology (Oxford), 44, 1205, 10.1093/rheumatology/kei103 · doi:10.1093/rheumatology/kei103
- Lv, 2014, The status of rheumatoid factor and anti-cyclic citrullinated peptide antibody are not associated with the effect of anti-TNFα agent treatment in patients with rheumatoid arthritis: a meta-analysis, PLoS One, 9, e89422, 10.1371/journal.pone.0089442 · doi:10.1371/journal.pone.0089442
- Coulthard, 2013, Differential effects of infliximab on absolute circulating blood leucocyte counts of innate immune cells in early and late rheumatoid arthritis patients, Clin Exp Immunol, 170, 36, 10.1111/j.1365-2249.2012.04626.x · doi:10.1111/j.1365-2249.2012.04626.x
- Sandborn, 2013, A special meeting review edition: clinical research highlights in ibd: diagnosis and anti-tumor necrosis factor monitoring, Gastroenterol Hepatol, 9, 1
- Thomas, 2014, Association of rs1568885, rs1813443 and rs4411591 polymorphisms with anti-TNF medication response in Greek patients with Crohn's disease, World J Gastroenterol, 20, 3609, 10.3748/wjg.v20.i13.3609 · doi:10.3748/wjg.v20.i13.3609
- Coulthard, 2011, Genetic variants within the MAP kinase signalling network and anti-TNF treatment response in rheumatoid arthritis patients, Ann Rheum Dis, 70, 98, 10.1136/ard.2010.133249 · doi:10.1136/ard.2010.133249
- Sedger, 2006, Poxviral tumour necrosis factor receptor (TNFR)-like T2 proteins contain a concerved pre-ligand association domain (PLAD) that inhibits cellular TNFR2 induced cell death, J Virol, 80, 9300, 10.1128/JVI.02449-05 · DOI
- Macen, 1996, Expression of the myxoma virus tumor necrosis factor receptor homologue and M11L genes is required to prevent virus-induced apoptosis in infected rabbit T lymphocytes, Virology, 218, 232, 10.1006/viro.1996.0183 · doi:10.1006/viro.1996.0183
- Coulthard, 2012, Differential effects of infliximab on absolute circulating blood leucocyte counts of innate immune cells in early and late rheumatoid arthritis patients, Clin Exp Immunol, 170, 36, 10.1111/j.1365-2249.2012.04626.x · doi:10.1111/j.1365-2249.2012.04626.x
- Tobinick, 2010, Perispinal etanercept: a new therapeutic paradigm in neurology, Expert Rev Neurother, 10, 985, 10.1586/ern.10.52 · DOI
- Schabert, 2013, Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population, J Manag Care Pharm, 19, 621, 10.18553/jmcp.2013.19.8.621 · doi:10.18553/jmcp.2013.19.8.621
- Grover, 2012, Pharmaceutical companies and global lack of access to medicines: strengthening accountability under the right to health, J Law Med Ethics, 40, 234, 10.1111/j.1748-720X.2012.00661.x · doi:10.1111/j.1748-720x.2012.00661.x
- Deighton, 2010, BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy, Rheumatology (Oxford), 49, 1197, 10.1093/rheumatology/keq006a · doi:10.1093/rheumatology/keq006a
- Scott, 2009, NICE guidelines on anti-tumor necrosis factor therapy for RA, Nat Clin Pract Rheumatol, 5, 16, 10.1038/ncprheum0964 · doi:10.1038/ncprheum0964
- Nikas, 2003, Onercept. Serono., Curr Opin Investig Drugs, 4, 1369
- Davis, 2000, Treatment of rheumatoid arthritis with PEGylated recombinant human soluble tumour necrosis factor receptor type I: a clinical update, Ann Rheum Dis, 59, 41, 10.1136/ard.59.suppl_1.i41 · doi:10.1136/ard.59.suppl_1.i41
Cited by
Jang, D.-I., Lee, A.-H., Shin, H.-Y., Song, H.-R., Park, J.-H., Kang, T.-B., Lee, S.-R., & Yang, S.-H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052719 · Cited by 1,694
The Semantics of Microglia Activation: Neuroinflammation, Homeostasis, and Stress
Woodburn, S. C., Bollinger, J. L., & Wohleb, E. S. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02309-6 · Cited by 783
Necroptosis: a regulated inflammatory mode of cell death
Dhuriya, Y. K., & Sharma, D. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1235-0 · Cited by 718
Particulate Matter Air Pollution: Effects on the Cardiovascular System
Hamanaka, R. B., & Mutlu, G. M. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00680 · Cited by 654
The role of IL-1β and TNF-α in intervertebral disc degeneration
Wang, Y., Che, M., Xin, J., Zheng, Z., Li, J., & Zhang, S. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110660 · Cited by 627
Metadata
- Authors
- Sedger, L. M., & McDermott, M. F.
- Venue
- Cytokine & Growth Factor Reviews
- Publisher
- Elsevier BV
- Published
- 2014-08
- Volume
- 25
- Issue
- 4
- Pages
- 453-472
- ISSN
- 1359-6101 (ISSN-L)
- OpenAlex
- W1964249139
- Cited by
- 771
- References
- 298
- FWCI
- 8.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/3.0/ (vor, 17 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.